; (D) effects of such shortages on beneficiaries enrolled in prescription drug plans under this part, including with respect to access to covered part D drugs and out-of-pocket costs; and (E) other issues determined appropriate by the Comptroller General. (2) Report Not later than 2 years after the date of enactment of this subsection, the Comptroller General shall submit to Congress a report containing the results of the study conducted under paragraph (1), together with recommendations for such legislation and administrative action as the Comptroller General determines appropriate. . 17. Report on biosimilar and generic access under Medicare part D Section 1860D–42 of the Social Security Act ( 42 U.S.C. 1395w–152 ), as amended by section 16, is amended by adding at the end the following new subsection: (k) OIG report on biosimilar and generic access under part d (1) Study The Office of the Inspector General of the Department of Health and Human Services (referred to in this subsection as the Office of the Inspector General ) shall conduct a study on biosimilar and generic drug access and adoption under prescription drug plans offered under this part, including with respect to barriers to increased adoption and utilization of lower-priced biosimilar and generic utilization, plan features that discourage or encourage the utilization of these products, and the gross and net spending effects of policies that increased adoption of these products under this part. (2) Report Not later than 1 year after the date of enactment of this subsection, the Office of the Inspector General shall publish a report on the study conducted under paragraph (1). . 18. Medicare Improvement Fund Section 1898(b)(1) of the Social Security Act ( 42 U.S.C. 1395iii(b)(1) ) is amended by striking during and after fiscal year 2022, $180,000,000 and inserting the following: “during and after— (A) fiscal year 2022, $180,000,000; and (B) fiscal year 2028, $1,947,000,000 .